论文部分内容阅读
目的 为了研究非小细胞肺癌组织中CyclinB1及P34 cdc2 的表达 ,探讨CyclinB1及P34 cdc2 的表达与非小细胞肺癌临床病理特征的关系。方法 随机收集非小细胞肺癌 (含癌旁细支气管和 /或小支气管增生组织和正常肺组织 )标本10 0例。采用免疫组织化学SP法。结果 显示在癌组织与癌旁细支气管和 /或小支气管上皮增生组织及正常肺组织中CyclinB1及P34 cdc2 表达差异有显著性 (P <0 0 1)。在癌组织中有过表达 ;在癌旁细支气管和 /或小支气管上皮增生组织中的表达较正常肺组织中的表达增强。 10 0例非小细胞肺癌组织中CyclinB1及P34 cdc2 表达呈正相关 (P <0 0 1) ,相关系数为 0 96 6。癌旁细支气管和 /或小支气管上皮增生组织中 ,CyclinB1及P34 cdc2 的表达也呈正相关 (P <0 0 1) ,相关系数为 0 6 38。组织类型、分化程度和淋巴结转移与CyclinB1及P34 cdc2 的表达均无统计学意义 (P >0 0 5 )。不同临床分期的非小细胞肺癌 ,其CyclinB1及P34 cdc2 的表达差异有显著性 (P <0 0 5 )。结论 CyclinB1及P34 cdc2 在非小细胞肺癌中有过表达现象 ,二者在M期前形成过多的促成熟因子 (maturationpromotingfactor,MPF)从而加速非小细胞肺癌细胞跨越G2 /M期关卡进入分裂期。过表达的CyclinB1及P34 cdc2 可作为反?
Objective To study the expression of CyclinB1 and P34 cdc2 in non-small cell lung cancer (NSCLC) and the relationship between the expression of CyclinB1 and P34 cdc2 and clinicopathological features of non-small cell lung cancer. Methods A total of 100 specimens of non-small cell lung cancer (including fine bronchioles and / or bronchial hyperplasia tissues and normal lung tissues) were randomly collected. Using immunohistochemical SP method. The results showed that the expression of CyclinB1 and P34 cdc2 was significantly different between cancer tissues and adjacent bronchioles and / or bronchial epithelial hyperplasia tissues and normal lung tissues (P <0.01). It was overexpressed in cancerous tissues. The expression in cancerous bronchioles and / or bronchial epithelial hyperplasia tissues was increased as compared with that in normal lung tissues. There was a positive correlation between the expression of CyclinB1 and P34 cdc2 in 10 0 non-small cell lung cancer (P <0.01), with a correlation coefficient of 0 966. The expression of CyclinB1 and P34 cdc2 also showed a positive correlation (P <0.01) in paracancerous bronchioles and / or bronchial epithelial hyperplasia, with a correlation coefficient of 0 6 38. The expression of CyclinB1 and P34 cdc2 was not statistically significant in histological type, differentiation and lymph node metastasis (P> 0.05). The expression of CyclinB1 and P34 cdc2 in different clinical stages of NSCLC was significantly different (P <0.05). Conclusions CyclinB1 and P34 cdc2 are overexpressed in non-small cell lung cancer (NSCLC). Both of them may form excessive maturation factor (MPF) before M phase, which will accelerate the progression of non-small cell lung cancer cells beyond the G2 / M phase into the dividing stage . Overexpression of CyclinB1 and P34 cdc2 can be used as reverse?